According to WHO statistics, there are around more than 350 million people are infected with chronic hepatitis B. Studies have shown that the highest levels of viral load of hepatitis B patients eventually developed cirrhosis and liver cancer risk increased significantly. With the rapid development of medicine, the treatment of chronic hepatitis B patients getting better and better prospects for a few days ago, the United States Institute announced the world’s first liver-specific progressed to decompensated cirrhosis, chronic hepatitis B patients with antiviral therapy and security studies, and once again recommends Baraclude (entecavir tablets) for long-term treatment of chronic hepatitis B patients with the best choice.

■ 80% of primary liver cancer and hepatitis B virus infection

The liver function is essential for human life. As the largest solid organ in the body, the liver has more than 500 kinds of features, including the fight against infection and disease, controlling cholesterol generation and discharge, clear the blood of waste, drugs and other toxic substances.

According to statistics, every year about one million patients with hepatitis B because it has not received medical treatment. Hepatitis B through blood and other body fluids to spread, such as semen, vaginal secretions, saliva, sores, as well as milk. 90% of the population can be formed within a few months hepatitis B virus (HBV) immunity and clear the virus, but some people can not. These people become carriers of the virus and may develop into chronic hepatitis. The first cause of chronic hepatitis B liver infections, leading to healthy liver cell damage, scar tissue formation, damage to liver function. Most patients with hepatitis B do not show any symptoms, so some persons infected with chronic hepatitis B virus infection after many years were ignorant.

Suffering from cirrhosis of the liver with chronic hepatitis B infection and liver cancer risk is higher. On a global scale, up to 80% of primary liver cancer (almost always be fatal) and the hepatitis B virus infection. Hepatitis B virus liver disease and of liver cancer is the world’s leading cause of death.

■ liver decompensation is very slim hope of cure

5% -7% each year with hepatitis B virus-related cirrhosis of the liver from compensatory to decompensated. Once the liver decompensation, cure would like to rather slim. Severe liver injury, including the impact of weight loss, fatigue, weakness, increased risk of severe bleeding, most patients will die of liver decompensation. Hepatic decompensation in patients with an average survival period of two years, the survival period of five years, the percentage of patients with only 28%.

Symptoms of liver decompensation include:

Jaundice (yellowing of skin or sclera)

Ascites (abnormal accumulation of water caused by abdominal distension)

Esophageal varicose veins (varicose blood vessels may result in potentially fatal bleeding)

Hepatic encephalopathy (neuropsychiatric abnormalities caused by personality changes, intellectual decline, confusion)

■ potent and lasting viral suppression is a delay or reverse the underlying disease progression of hepatitis B

In view of the progress of chronic hepatitis B-related disease on patients the health effects of China’s “Guide to prevention and treatment of chronic hepatitis B,” it clear that the overall goal of the treatment of chronic hepatitis B is: as much as possible long-term suppression or elimination of hepatitis B virus, reducing inflammation and necrosis of liver cells, and liver fibrosis, delay and prevent disease progression, reduce and prevent liver decompensation, liver cirrhosis, liver cancer and its complications, thereby improving the quality of life and extend survival time.

Disease progression of chronic hepatitis B, mainly due to hepatitis B virus infection caused by chronic inflammation caused by, but the current medical standards not yet completely clear the body of the hepatitis B virus. Therefore, potent and sustained suppression of hepatitis B virus, which is to improve the liver tissue, and then slow down or even reverse the disease progression of hepatitis B lies.

Numerous studies confirmed that the powerful and lasting viral suppression, which would enable the vast majority of patients with chronic hepatitis B under control, curb disease, cirrhosis or liver cancer to develop in the direction; the other hand, can help patients with disease progression has occurred, to reduce inflammation, improve or even reverse fibrosis and improve patient survival.

At the 60th AASLD Annual Meeting to the latest clinical trial research shows that people with decompensated liver cirrhosis, chronic hepatitis B patients receive long-term Baraclude (entecavir tablets) treatment, not only has a good safety and tolerance, but also significantly reduce the viral load and improve the clinical indicators of liver function. The published studies, is the world’s first specifically progressed to decompensated cirrhosis, chronic hepatitis B patients, to assess its anti-virus treatment efficacy and safety study.

■ prevention of drug-resistant, so powerful and lasting viral suppression is possible

The progress of chronic hepatitis B and its related diseases in the anti-viral treatment, it is also faced with resistance to the biggest “stumbling block.” In the treatment of drug resistance could occur at any stage. The event of resistance, the virus re-active replication, causing disease progression, so that antiviral therapy come to naught. Due to the presence of cross-resistance in case of resistance, but also limits the choice of treatment in patients with follow-up.

Therefore, many parts of the world’s hepatitis B treatment guidelines have pointed out that the progress of hepatitis B and related diseases in patients with antiviral therapy should be to prevent drug resistance, the preferred high genetic barrier, low resistance rates of drugs. Therefore, patients with hepatitis B should be taken to prevent drug resistance strategies, emphasis on the initial treatment of choice from the outset, powerful anti-virus and a high barrier of drug resistance genes in order to achieve long-term stability of hepatitis B disease control and continuously improve their own lives quality.